Novel insights into the ecDNA formation mechanism involving MSH3 in methotrexate‑resistant human colorectal cancer cells

Wang,Xu; Qu,Yanan; Xing,Ruonan; Zhou,Jing; Liu,Yanghe; Zhang,Huishu; Zhu,Jing; Ma,Jinfa; Cui,Xiaobo; Song,Tiantian; Xing,Shukai; Ji,Guohua; Liu,Peng; Sun,Wenjing; Fu,Songbin; Meng,Xiangning

doi:10.3892/ijo.2023.5582

Novel insights into the ecDNA formation mechanism involving MSH3 in methotrexate‑resistant human colorectal cancer cells

Authors:
- Xu Wang
- Yanan Qu
- Ruonan Xing
- Jing Zhou
- Yanghe Liu
- Huishu Zhang
- Jing Zhu
- Jinfa Ma
- Xiaobo Cui
- Tiantian Song
- Shukai Xing
- Guohua Ji
- Peng Liu
- Wenjing Sun
- Songbin Fu
- Xiangning Meng
View Affiliations

Affiliations: Laboratory of Medical Genetics, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
Published online on: October 20, 2023 https://doi.org/10.3892/ijo.2023.5582
Article Number: 134
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Extrachromosomal DNAs (ecDNAs), also known as double minutes (DMs), can induce a fast increase in gene copy numbers and promote the development of cancer, including drug resistance. MutS homolog 3 (MSH3), a key protein in mismatch repair, has been indicated to participate in the regulation of DNA double‑strand break (DSB) repair, which has been reported to be associated with the formation of ecDNAs. However, it remains unclear whether MSH3 can influence drug resistance via ecDNAs in cancer. In the present study, high MSH3 expression was observed in methotrexate (MTX)‑resistant HT29 cells [DM‑ and homogeneously staining region (HSR)‑containing cells] compared with parental HT29 cells. Additionally, decreased amounts of ecDNAs, HSRs and amplified genes locating on ecDNAs and HSRs were detected following depletion of MSH3 and this could be reversed by overexpressing MSH3 in DM‑containing cells. No corresponding changes were found in HSR‑containing cells. The present study further verified the involvement of MSH3‑regulated DNA DSB repair pathways in the formation of ecDNAs by detecting the expression of core proteins and pathway activity. Furthermore, expulsion of ecDNAs/HSRs was detected and increased frequencies of micronuclei/nuclear buds with dihydrofolate reductase (DHFR) signals were observed in MSH3‑depleted DM‑containing cells. Finally, changes in MSH3 expression could affect DHFR amplification‑derived DHFR expression and cell sensitivity to MTX, suggesting that MSH3 may influence cancer drug resistance by altering the amount of ecDNAs. In conclusion, the present study revealed a novel mechanism involving MSH3 in the regulation of ecDNAs by DSB repair, which will have clinical value in the treatment of ecDNA‑based drug resistance in cancer.

View Figures

View References

1	Albertson DG: Gene amplification in cancer. Trends Genet. 22:447–455. 2006.
2	Storlazzi CT, Lonoce A, Guastadisegni MC, Trombetta D, D'Addabbo P, Daniele G, L'Abbate A, Macchia G, Surace C, Kok K, et al: Gene amplification as double minutes or homogeneously staining regions in solid tumors: Origin and structure. Genome Res. 20:1198–1206. 2010.
3	Benner SE, Wahl GM and Von Hoff DD: Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs. 2:11–25. 1991.
4	Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, et al: Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 543:122–125. 2017.
5	Menghi F, Barthel FP, Yadav V, Tang M, Ji B, Tang Z, Carter GW, Ruan Y, Scully R, Verhaak RGW, et al: The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations. Cancer Cell. 34:197–210.e5. 2018.
6	Gisselsson D, Jin Y, Lindgren D, Persson J, Gisselsson L, Hanks S, Sehic D, Mengelbier LH, Øra I, Rahman N, et al: Generation of trisomies in cancer cells by multipolar mitosis and incomplete cytokinesis. Proc Natl Acad Sci USA. 107:20489–20493. 2010.
7	Korbel JO and Campbell PJ: Criteria for inference of chromothripsis in cancer genomes. Cell. 152:1226–1236. 2013.
8	Meng X, Qi X, Guo H, Cai M, Li C, Zhu J, Chen F, Guo H, Li J, Zhao Y, et al: Novel role for non-homologous end joining in the formation of double minutes in methotrexate-resistant colon cancer cells. J Med Genet. 52:135–144. 2015.
9	Cai M, Zhang H, Hou L, Gao W, Song Y, Cui X, Li C, Guan R, Ma J, Wang X, et al: Inhibiting homologous recombination decreases extrachromosomal amplification but has no effect on intrachromosomal amplification in methotrexate-resistant colon cancer cells. Int J Cancer. 144:1037–1048. 2019.
10	Hong Z, Jiang J, Hashiguchi K, Hoshi M, Lan L and Yasui A: Recruitment of mismatch repair proteins to the site of DNA damage in human cells. J Cell Sci. 121:3146–3154. 2008.
11	Surtees JA and Alani E: Mismatch repair factor MSH2-MSH3 binds and alters the conformation of branched DNA structures predicted to form during genetic recombination. J Mol Biol. 360:523–536. 2006.
12	Lyndaker AM and Alani E: A tale of tails: Insights into the coordination of 3' end processing during homologous recombination. Bioessays. 31:315–321. 2009.
13	Takahashi M, Koi M, Balaguer F, Boland CR and Goel A: MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem. 286:12157–12165. 2011.
14	Dillon LW, Kumar P, Shibata Y, Wang YH, Willcox S, Griffith JD, Pommier Y, Takeda S and Dutta A: Production of extrachromosomal MicroDNAs is linked to mismatch repair pathways and transcriptional activity. Cell Rep. 11:1749–1759. 2015.
15	Von Hoff DD, McGill JR, Forseth BJ, Davidson KK, Bradley TP, Van Devanter DR and Wahl GM: Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci USA. 89:8165–8169. 1992.
16	Eckhardt SG, Dai A, Davidson KK, Forseth BJ, Wahl GM and Von Hoff DD: Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc. Proc Natl Acad Sci USA. 91:6674–6678. 1994.
17	Shimizu N, Shimura T and Tanaka T: Selective elimination of acentric double minutes from cancer cells through the extrusion of micronuclei. Mutat Res. 448:81–90. 2000.
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
19	Pierce AJ, Hu P, Han M, Ellis N and Jasin M: Ku DNA end- binding protein modulates homologous repair of double-strand breaks in mammalian cells. Genes Dev. 15:3237–3242. 2001.
20	Bennardo N, Cheng A, Huang N and Stark JM: Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 4:e10001102008.
21	Morales C, García MJ, Ribas M, Miró R, Muñoz M, Caldas C and Peinado MA: Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells. Mol Cancer Ther. 8:424–432. 2009.
22	Chang DK, Ricciardiello L, Goel A, Chang CL and Boland CR: Steady-state regulation of the human DNA mismatch repair system. J Biol Chem. 275:18424–18431. 2000.
23	Syed A and Tainer JA: The MRE11-RAD50-NBS1 complex conducts the orchestration of damage signaling and outcomes to stress in DNA replication and repair. Annu Rev Biochem. 87:263–294. 2018.
24	Startek M, Szafranski P, Gambin T, Campbell IM, Hixson P, Shaw CA, Stankiewicz P and Gambin A: Genome-wide analyses of LINE-LINE-mediated nonallelic homologous recombination. Nucleic Acids Res. 43:2188–2198. 2015.
25	Simsek D and Jasin M: Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4-ligase IV during chromosomal translocation formation. Nat Struct Mol Biol. 17:410–416. 2010.
26	Sallmyr A and Tomkinson AE: Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem. 293:10536–10546. 2018.
27	Kisurina-Evgenieva OP, Sutiagina OI and Onishchenko GE: Biogenesis of Micronuclei. Biochemistry (Mosc). 81:453–464. 2016.
28	Morales C, Ribas M, Aiza G and Peinado MA: Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells. Oncogene. 24:6842–6847. 2005.
29	Zhang Y, Dong K, Jia X, Du S, Wang D, Wang L, Qu H, Zhu S, Wang Y, Wang Z, et al: A novel extrachromosomal circular DNA related genes signature for overall survival prediction in patients with ovarian cancer. BMC Med Genomics. 16:1402023.
30	Hung KL, Yost KE, Xie L, Shi Q, Helmsauer K, Luebeck J, Schöpflin R, Lange JT, Chamorro González R, Weiser NE, et al: ecDNA hubs drive cooperative intermolecular oncogene expression. Nature. 600:731–736. 2021.
31	Jiricny J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 7:335–346. 2006.
32	Jiricny J: Postreplicative mismatch repair. Cold Spring Harb Perspect Biol. 5:a0126332013.
33	Chatterjee N, Lin Y and Wilson JH: Mismatch repair enhances convergent transcription-induced cell death at trinucleotide repeats by activating ATR. DNA Repair (Amst). 42:26–32. 2016.
34	Bannister LA, Waldman BC and Waldman AS: Modulation of error-prone double-strand break repair in mammalian chromosomes by DNA mismatch repair protein Mlh1. DNA Repair (Amst). 3:465–474. 2004.
35	Zhu J, Yu Y, Meng X, Fan Y, Zhang Y, Zhou C, Yue Z, Jin Y, Zhang C, Yu L, et al: De novo-generated small palindromes are characteristic of amplicon boundary junction of double minutes. Int J Cancer. 133:797–806. 2013.
36	Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C and Munshi NC: Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood. 113:2290–2297. 2009.
37	Marti TM, Kunz C and Fleck O: DNA mismatch repair and mutation avoidance pathways. J Cell Physiol. 191:28–41. 2002.
38	Li GM: Mechanisms and functions of DNA mismatch repair. Cell Res. 18:85–98. 2008.
39	Lieber MR: The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 79:181–211. 2010.
40	Smith JA, Waldman BC and Waldman AS: A role for DNA mismatch repair protein Msh2 in error-prone double-strand-break repair in mammalian chromosomes. Genetics. 170:355–363. 2005.
41	Shahi A, Lee JH, Kang Y, Lee SH, Hyun JW, Chang IY, Jun JY and You HJ: Mismatch-repair protein MSH6 is associated with Ku70 and regulates DNA double-strand break repair. Nucleic Acids Res. 39:2130–2143. 2011.
42	Stavnezer J and Schrader CE: Mismatch repair converts AID-instigated nicks to double-strand breaks for antibody class-switch recombination. Trends Genet. 22:23–28. 2006.
43	Schrader CE, Guikema JE, Linehan EK, Selsing E and Stavnezer J: Activation-induced cytidine deaminase-dependent DNA breaks in class switch recombination occur during G1 phase of the cell cycle and depend upon mismatch repair. J Immunol. 179:6064–6071. 2007.
44	Eccleston J, Schrader CE, Yuan K, Stavnezer J and Selsing E: Class switch recombination efficiency and junction microhomology patterns in Msh2-, Mlh1-, and Exo1-deficient mice depend on the presence of mu switch region tandem repeats. J Immunol. 183:1222–1228. 2009.
45	Della-Maria J, Zhou Y, Tsai MS, Kuhnlein J, Carney JP, Paull TT and Tomkinson AE: Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. J Biol Chem. 286:33845–33853. 2011.
46	Eccleston J, Yan C, Yuan K, Alt FW and Selsing E: Mismatch repair proteins MSH2, MLH1, and EXO1 are important for class-switch recombination events occurring in B cells that lack nonhomologous end joining. J Immunol. 186:2336–2343. 2011.
47	Terradas M, Martín M and Genescà A: Impaired nuclear functions in micronuclei results in genome instability and chromothripsis. Arch Toxicol. 90:2657–2667. 2016.
48	Shimizu N, Kanda T and Wahl GM: Selective capture of acentric fragments by micronuclei provides a rapid method for purifying extrachromosomally amplified DNA. Nat Genet. 12:65–71. 1996.
49	Shimizu N, Itoh N, Utiyama H and Wahl GM: Selective entrapment of extrachromosomally amplified DNA by nuclear budding and micronucleation during S phase. J Cell Biol. 140:1307–1320. 1998.
50	Shimizu N, Misaka N and Utani K: Nonselective DNA damage induced by a replication inhibitor results in the selective elimination of extrachromosomal double minutes from human cancer cells. Genes Chromosomes Cancer. 46:865–874. 2007.
51	Canute GW, Longo SL, Longo JA, Winfield JA, Nevaldine BH and Hahn PJ: Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme. Neurosurgery. 39:976–983. 1996.
52	Ambros IM, Rumpler S, Luegmayr A, Hattinger CM, Strehl S, Kovar H, Gadner H and Ambros PF: Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation-sign of tumour cell revertance? Eur J Cancer. 33:2043–2049. 1997.
53	Prochazka P, Hrabeta J, Vícha A and Eckschlager T: Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine. Cancer Genet Cytogenet. 196:96–104. 2010.
54	Sawant A, Kothandapani A, Zhitkovich A, Sobol RW and Patrick SM: Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. DNA Repair (Amst). 35:126–136. 2015.